Long-term survival in typical thanatophoric dysplasia type 1

Kristin M. Baker, David S. Olson, Cary Harding, Richard M. Pauli

Research output: Contribution to journalArticle

68 Citations (Scopus)

Abstract

Thanatophoric dysplasia (TD), a severe skeletal dysplasia, is virtually always lethal neonatally, although a few previous reports have documented survival up to 4.75 years. We present a patient with survival beyond age 9 years and summarize his growth, development and medical history. The common Arg248Cys mutation in the extracellular region of fibroblast growth factor receptor 3 (FGFR3) was identified, eliminating the possibility that his long- term survival is attributable to an atypical mutation. This patient (and at least one other TD long-term survivor) have a rare skin disorder, acanthosis nigricans, which also occurs in Crouzon syndrome when caused by a FGFR3 mutation. Therefore, any molecular model of the origin of acanthosis nigricans secondary to FGFR3 mutations must account for the association of diverse mutations and these cutaneous effects.

Original languageEnglish (US)
Pages (from-to)427-436
Number of pages10
JournalAmerican Journal of Medical Genetics
Volume70
Issue number4
DOIs
StatePublished - Jun 27 1997
Externally publishedYes

Fingerprint

Receptor, Fibroblast Growth Factor, Type 3
Thanatophoric Dysplasia
Mutation
Survival
Acanthosis Nigricans
Craniofacial Dysostosis
Skin
Molecular Models
Growth and Development
Survivors
Type I Thanatophoric Dysplasia

Keywords

  • Acanthosis nigricans
  • Craniosynostosis
  • Fibroblast growth factor receptor 3 (FGFR3)
  • Lethality
  • One dysplasias
  • Thanatophoric dysplasia
  • Unexpected survival

ASJC Scopus subject areas

  • Genetics(clinical)

Cite this

Long-term survival in typical thanatophoric dysplasia type 1. / Baker, Kristin M.; Olson, David S.; Harding, Cary; Pauli, Richard M.

In: American Journal of Medical Genetics, Vol. 70, No. 4, 27.06.1997, p. 427-436.

Research output: Contribution to journalArticle

Baker, Kristin M. ; Olson, David S. ; Harding, Cary ; Pauli, Richard M. / Long-term survival in typical thanatophoric dysplasia type 1. In: American Journal of Medical Genetics. 1997 ; Vol. 70, No. 4. pp. 427-436.
@article{039c82913f0a4fd9ba31ae45f5d0e03f,
title = "Long-term survival in typical thanatophoric dysplasia type 1",
abstract = "Thanatophoric dysplasia (TD), a severe skeletal dysplasia, is virtually always lethal neonatally, although a few previous reports have documented survival up to 4.75 years. We present a patient with survival beyond age 9 years and summarize his growth, development and medical history. The common Arg248Cys mutation in the extracellular region of fibroblast growth factor receptor 3 (FGFR3) was identified, eliminating the possibility that his long- term survival is attributable to an atypical mutation. This patient (and at least one other TD long-term survivor) have a rare skin disorder, acanthosis nigricans, which also occurs in Crouzon syndrome when caused by a FGFR3 mutation. Therefore, any molecular model of the origin of acanthosis nigricans secondary to FGFR3 mutations must account for the association of diverse mutations and these cutaneous effects.",
keywords = "Acanthosis nigricans, Craniosynostosis, Fibroblast growth factor receptor 3 (FGFR3), Lethality, One dysplasias, Thanatophoric dysplasia, Unexpected survival",
author = "Baker, {Kristin M.} and Olson, {David S.} and Cary Harding and Pauli, {Richard M.}",
year = "1997",
month = "6",
day = "27",
doi = "10.1002/(SICI)1096-8628(19970627)70:4<427::AID-AJMG18>3.0.CO;2-J",
language = "English (US)",
volume = "70",
pages = "427--436",
journal = "American Journal of Medical Genetics, Part A",
issn = "1552-4825",
publisher = "Wiley-Liss Inc.",
number = "4",

}

TY - JOUR

T1 - Long-term survival in typical thanatophoric dysplasia type 1

AU - Baker, Kristin M.

AU - Olson, David S.

AU - Harding, Cary

AU - Pauli, Richard M.

PY - 1997/6/27

Y1 - 1997/6/27

N2 - Thanatophoric dysplasia (TD), a severe skeletal dysplasia, is virtually always lethal neonatally, although a few previous reports have documented survival up to 4.75 years. We present a patient with survival beyond age 9 years and summarize his growth, development and medical history. The common Arg248Cys mutation in the extracellular region of fibroblast growth factor receptor 3 (FGFR3) was identified, eliminating the possibility that his long- term survival is attributable to an atypical mutation. This patient (and at least one other TD long-term survivor) have a rare skin disorder, acanthosis nigricans, which also occurs in Crouzon syndrome when caused by a FGFR3 mutation. Therefore, any molecular model of the origin of acanthosis nigricans secondary to FGFR3 mutations must account for the association of diverse mutations and these cutaneous effects.

AB - Thanatophoric dysplasia (TD), a severe skeletal dysplasia, is virtually always lethal neonatally, although a few previous reports have documented survival up to 4.75 years. We present a patient with survival beyond age 9 years and summarize his growth, development and medical history. The common Arg248Cys mutation in the extracellular region of fibroblast growth factor receptor 3 (FGFR3) was identified, eliminating the possibility that his long- term survival is attributable to an atypical mutation. This patient (and at least one other TD long-term survivor) have a rare skin disorder, acanthosis nigricans, which also occurs in Crouzon syndrome when caused by a FGFR3 mutation. Therefore, any molecular model of the origin of acanthosis nigricans secondary to FGFR3 mutations must account for the association of diverse mutations and these cutaneous effects.

KW - Acanthosis nigricans

KW - Craniosynostosis

KW - Fibroblast growth factor receptor 3 (FGFR3)

KW - Lethality

KW - One dysplasias

KW - Thanatophoric dysplasia

KW - Unexpected survival

UR - http://www.scopus.com/inward/record.url?scp=0031004013&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031004013&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1096-8628(19970627)70:4<427::AID-AJMG18>3.0.CO;2-J

DO - 10.1002/(SICI)1096-8628(19970627)70:4<427::AID-AJMG18>3.0.CO;2-J

M3 - Article

VL - 70

SP - 427

EP - 436

JO - American Journal of Medical Genetics, Part A

JF - American Journal of Medical Genetics, Part A

SN - 1552-4825

IS - 4

ER -